Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 45,006,000 | 46,159,000 | 46,385,000 | 42,518,000 | 26,145,000 |
| Cost of Goods | 10,693,000 | 10,137,000 | 9,940,000 | 11,773,000 | 8,078,000 |
| Gross Profit | 34,313,000 | 36,022,000 | 36,445,000 | 30,745,000 | 18,067,000 |
| Operating Expenses | 25,873,000 | 28,309,000 | 28,347,000 | 37,616,000 | 13,092,000 |
| Operating Income | 8,440,000 | 7,713,000 | 8,098,000 | -6,871,000 | 4,975,000 |
| Pre-tax Income | 8,440,000 | 7,713,000 | 8,098,000 | -6,871,000 | 4,975,000 |
| Income Tax | 400,000 | 1,368,000 | 1,084,000 | 2,124,000 | 1,515,000 |
| Net Income Continuous | 8,040,000 | 6,345,000 | 7,014,000 | -8,995,000 | 3,460,000 |
| Minority Interests | 15,000 | 18,000 | 20,000 | 20,000 | 21,000 |
| Net Income | $8,025,000 | $6,327,000 | $6,994,000 | $-9,015,000 | $3,439,000 |
| EPS Basic Total Ops | 3.88 | 2.97 | 3.15 | -3.99 | 2.02 |
| EPS Basic Continuous Ops | 3.89 | 2.98 | 3.16 | -3.98 | 2.03 |
| EPS Diluted Total Ops | 3.86 | 2.95 | 3.12 | -3.99 | 2.01 |
| EPS Diluted Continuous Ops | 3.87 | 2.96 | 3.12 | -3.98 | 2.02 |
| EPS Diluted Before Non-Recurring Items | 7.51 | 7.70 | 7.51 | 6.44 | 4.69 |
| EBITDA(a) | $18,200,000 | $17,989,000 | $18,784,000 | $3,509,000 | $6,721,000 |